Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. Indication coverage (lipid-lowering and cardiovascular risk reduction) and statin class safety signals (liver enzymes, muscle toxicity) are supported. Pharmacokinetics/drug-interactions facets referencing increased exposure from interactions are acknowledged. However, critical safety elements (pregnancy contraindication, boxed warning for interactions, pediatric safety/dosing, hepatic impairment dosing guidance) are omitted, and sleep-aid specific interactions are not supported by labeling.
Category Scores
Accurate Statements
Lipitor is a prescription medication used to lower cholesterol.
1.2
Lipitor is a prescription medication used to prevent heart disease.
1.1
Lipitor is a member of the statin class of medications.
5.1
Statins can affect liver enzymes.
5.2
Statins can increase the risk of muscle damage.
5.1
Slower liver metabolism can lead to increased levels of Lipitor in the body.
7.1,12.3
Increased Lipitor levels can cause muscle damage.
5.1
Increased Lipitor levels can cause elevated liver enzymes.
5.2
Increased Lipitor levels can cause kidney damage.
5.1
Unsupported Statements
Lipitor can interact with sleep aids.
No sleep-aid interactions documented in label.
Interactions between Lipitor and sleep aids can cause adverse effects.
No sleep-aid interaction adverse effects described.
There have been reports of adverse effects when Lipitor is taken with sleep aids.
Sleep-aid related adverse events not documented in label.
Muscle pain and weakness are adverse effects reported with Lipitor-sleep aid use.
Sleep-aid specific attribution not described.
Elevated liver enzymes are adverse effects reported with Lipitor-sleep aid use.
No sleep-aid attribution.
Kidney damage is adverse effects reported with Lipitor-sleep aid use.
No sleep-aid attribution.
Interactions with other medications, such as blood thinners, have been reported with Lipitor-sleep aid use.
Sleep-aid interactions not described.
Increased risk of bleeding or bruising with Lipitor-sleep aid use.
No sleep-aid interaction described.
Monitoring liver function and kidney health is advised for patients taking Lipitor and sleep aids.
Sleep-aid combined monitoring not described.
Adjusting the dosage of Lipitor or sleep aids if necessary.
Sleep-aid specific dosing guidance not described.
Avoiding high doses of certain sleep aids, like benzodiazepines.
Sleep aids dosing guidance not described.
Considering alternative sleep aids, such as non-benzodiazepine sedatives or natural sleep aids.
Not part of labeling guidance for Lipitor.
FDA warns of potential interactions between Lipitor and certain sleep aids.
No sleep-aid interaction warning in label.
Contradictions
Important Omissions
Pregnancy risk and fetal harm; Lipitor is contraindicated in pregnancy.
Importance:
High
Boxed warning for risk of myopathy/rhabdomyolysis with concomitant therapies (strong CYP3A4 inhibitors).
Importance:
High
Pediatric safety and dosing (e.g., ≥10 years with heterozygous familial hypercholesterolemia).
Importance:
High
Dosing safety and adjustments in hepatic impairment.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Sleep-aid related claims are largely unsupported; however major safety aspects (pregnancy contraindication, boxed warning, pediatric use, hepatic impairment dosing) are omitted from the claims evaluation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Critical safety omissions identified (pregnancy contraindication, boxed warning, pediatric use, hepatic impairment dosing) with sleep-aid interactions not covered.
Suggested Improvement
Incorporate complete safety labeling points (pregnancy and contraindications), ensure boxed-warning content is reflected, add pediatric dosing guidance, and address any sleep-aid interaction data explicitly.